|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: Epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
World Health Organization, . Guidelines
for the Prevention, Care and Treatment of Persons with Chronic
Hepatitis B Infection. 2015.
|
|
4
|
Levrero M and Zucman-Rossi J: Mechanisms
of HBV-induced hepatocellular carcinoma. J Hepatol. 64 (1
Suppl):S84–S101. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xu QG, Yuan SX, Tao QF, Yu J, Cai J, Yang
Y, Guo XG, Lin KY, Ma JZ, Dai DS, et al: A novel HBx genotype
serves as a preoperative predictor and fails to activate the
JAK1/STATs pathway in hepatocellular carcinoma. J Hepatol.
70:904–917. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xiao W, Wang RS, Handy DE and Loscalzo J:
NAD(H) and NADP(H) redox couples and cellular energy metabolism.
Antioxid Redox Signal. 28:251–272. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yaku K, Okabe K and Nakagawa T: NAD
metabolism: Implications in aging and longevity. Ageing Res Rev.
47:1–17. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Garten A, Schuster S, Penke M, Gorski T,
de Giorgis T and Kiess W: Physiological and pathophysiological
roles of NAMPT and NAD metabolism. Nat Rev Endocrinol. 11:535–546.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sampath D, Zabka TS, Misner DL, O'Brien T
and Dragovich PS: Inhibition of nicotinamide
phosphoribosyltransferase (NAMPT) as a therapeutic strategy in
cancer. Pharmacol Ther. 151:16–31. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee J, Kim H, Lee JE, Shin SJ, Oh S, Kwon
G, Kim H, Choi YY, White MA, Paik S, et al: Selective cytotoxicity
of the NAMPT inhibitor FK866 toward gastric cancer cells with
markers of the epithelial-mesenchymal transition, due to loss of
NAPRT. Gastroenterology. 155:799–814 e13. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Espindola-Netto JM, Chini CCS, Tarrago M,
Wang E, Dutta S, Pal K, Mukhopadhyay D, Sola-Penna M and Chini EN:
Preclinical efficacy of the novel competitive NAMPT inhibitor
STF-118804 in pancreatic cancer. Oncotarget. 8:85054–85067. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gehrke I, Bouchard ED, Beiggi S, Poeppl
AG, Johnston JB, Gibson SB and Banerji V: On-target effect of
FK866, a nicotinamide phosphoribosyl transferase inhibitor, by
apoptosis-mediated death in chronic lymphocytic leukemia cells.
Clin Cancer Res. 20:4861–4872. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mo CF, Li J, Yang SX, Guo HJ, Liu Y, Luo
XY, Wang YT, Li MH, Li JY and Zou Q: IQGAP1 promotes anoikis
resistance and metastasis through Rac1-dependent ROS accumulation
and activation of Src/FAK signalling in hepatocellular carcinoma.
Br J Cancer. 123:1154–1163. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xu J, Liu H, Chen L, Wang S, Zhou L, Yun
X, Sun L, Wen Y and Gu J: Hepatitis B virus X protein confers
resistance of hepatoma cells to anoikis by up-regulating and
activating p21-activated kinase 1. Gastroenterology.
143:199–212.e4. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li K, Mo C, Gong D, Chen Y, Huang Z, Li Y,
Zhang J, Huang L, Li Y, Fuller-Pace FV, et al: DDX17
nucleocytoplasmic shuttling promotes acquired gefitinib resistance
in non-small cell lung cancer cells via activation of β-catenin.
Cancer Lett. 400:194–202. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak JK and Schmittgen Td: Analysis of
relative gene expression data using quantitative Pcr and the
2(-delta delta c(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li K, Gao B, Li J, Chen H, Li Y, Wei Y,
Gong D, Gao J, Zhang J, Tan W, et al: ZNF32 protects against
oxidative stress-induced apoptosis by modulating C1QBP
transcription. Oncotarget. 6:38107–38126. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ringelhan M, O'Connor T, Protzer U and
Heikenwalder M: The direct and indirect roles of HBV in liver
cancer: Prospective markers for HCC screening and potential
therapeutic targets. J Pathol. 235:355–367. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Buendia MA and Neuveut C: Hepatocellular
carcinoma. Cold Spring Harb Perspect Med. 5:a0214442015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mao X, Tey SK, Ko FCF, Kwong EML, Gao Y,
Ng IO, Cheung ST, Guan XY and Yam JWP: C-terminal truncated HBx
protein activates caveolin-1/LRP6/β-catenin/FRMD5 axis in promoting
hepatocarcinogenesis. Cancer Lett. 444:60–69. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Song X, Tan S, Wu Z, Xu L, Wang Z, Xu Y,
Wang T, Gao C, Gong Y, Liang X, et al: HBV suppresses ZHX2
expression to promote proliferation of HCC through miR-155
activation. Int J Cancer. 143:3120–3130. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li J, He J, Fu Y, Hu X, Sun LQ, Huang Y
and Fan X: Hepatitis B virus X protein inhibits apoptosis by
modulating endoplasmic reticulum stress response. Oncotarget.
8:96027–96034. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pallett LJ, Gill US, Quaglia A, Sinclair
LV, Jover-Cobos M, Schurich A, Singh KP, Thomas N, Das A, Chen A,
et al: Metabolic regulation of hepatitis B immunopathology by
myeloid-derived suppressor cells. Nat Med. 21:591–600. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fisicaro P, Boni C, Barili V, Laccabue D
and Ferrari C: Strategies to overcome HBV-specific T cell
exhaustion: Checkpoint inhibitors and metabolic re-programming.
Curr Opin Virol. 30:1–8. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gao R, Cheng J, Fan C, Shi X, Cao Y, Sun
B, Ding H, Hu C, Dong F and Yan X: Serum metabolomics to identify
the liver disease-specific biomarkers for the progression of
hepatitis to hepatocellular carcinoma. Sci Rep. 5:181752015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li H, Zhu W, Zhang L, Lei H, Wu X, Guo L,
Chen X, Wang Y and Tang H: The metabolic responses to hepatitis B
virus infection shed new light on pathogenesis and targets for
treatment. Sci Rep. 5:84212015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Schinzari V, Barnaba V and Piconese S:
Chronic hepatitis B virus and hepatitis C virus infections and
cancer: Synergy between viral and host factors. Clin Microbiol
Infect. 21:969–974. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ganesan M, Eikenberry A, Poluektova LY,
Kharbanda KK and Osna NA: Role of alcohol in pathogenesis of
hepatitis B virus infection. World J Gastroenterol. 26:883–903.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ying W, Alano CC, Garnier P and Swanson
RA: NAD+ as a metabolic link between DNA damage and cell death. J
Neurosci Res. 79:216–223. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Roulston A and Shore GC: New strategies to
maximize therapeutic opportunities for NAMPT inhibitors in
oncology. Mol Cell Oncol. 3:e10521802016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Griffiths HBS, Williams C, King SJ and
Allison SJ: Nicotinamide adenine dinucleotide (NAD+):
Essential redox metabolite, co-substrate and an anti-cancer and
anti-ageing therapeutic target. Biochem Soc Trans. 48:733–744.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yaku K, Okabe K, Hikosaka K and Nakagawa
T: NAD metabolism in cancer therapeutics. Front Oncol. 8:6222018.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jiang H, Cheng ST, Ren JH, Ren F, Yu HB,
Wang Q, Huang AL and Chen J: SIRT6 inhibitor, OSS_128167 restricts
hepatitis B virus transcription and replication through targeting
transcription factor peroxisome proliferator-activated receptors α.
Front Pharmacol. 10:12702019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ren JH, Tao Y, Zhang ZZ, Chen WX, Cai XF,
Chen K, Ko BC, Song CL, Ran LK, Li WY, et al: Sirtuin 1 regulates
hepatitis B virus transcription and replication by targeting
transcription factor AP-1. J Virol. 88:2442–2451. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pant K, Mishra AK, Pradhan SM, Nayak B,
Das P, Shalimar D, Saraya A and Venugopal SK: Butyrate inhibits HBV
replication and HBV-induced hepatoma cell proliferation via
modulating SIRT-1/Ac-p53 regulatory axis. Mol Carcinog. 58:524–532.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang Q, Cheng ST and Chen J: HBx mediated
increase of SIRT1 contributes to HBV-related hepatocellular
carcinoma tumorigenesis. Int J Med Sci. 17:1783–1794. 2020.
View Article : Google Scholar : PubMed/NCBI
|
